NCT02788240

To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase

To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase - A Randomized Controlled Study

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Institute of Liver and Biliary Sciences, India · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure) and who are willing to participate in the study would be enrolled. After performing baseline biochemical tests, patients will undergo transjugular liver biopsy (TJLB), HVPG (Hepatic Venous Pressure Gradient), Circulating CD34 cells, Bone marrow aspiration and biopsy (Histopathological and immunohistochemical examination will be done).

Conditions

• Acute on Chronic Liver Failure

Interventions

Type	Name	Description
DRUG	Peg GCSF
BIOLOGICAL	20% Albumin
DIETARY_SUPPLEMENT	Nutrition
OTHER	Bowel wash
DRUG	Terlipressin 1- 4mg,if indicated
DRUG	Meropenem or Imepenem, if indicated
DRUG	Placebo

Timeline

• Start date: 2016-05-01
• Primary completion: 2017-07-15
• Completion: 2017-07-15
• First posted: 2016-06-02
• Last updated: 2018-02-06

Locations

1 site across 1 country: India